Ralph Makar, the newly appointed president and CEO of Bioject, said: “We are pleased to enter into this new agreement with Merck Serono, which is the continuation of our successful relationship with them. Merck Serono has been an excellent partner and we appreciate the confidence Merck Serono has in our proprietary needle-free technology. We look forward to continuing to supply them with our value-added spring-powered device and disposables for their recombinant human growth hormone drugs.”